This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. | Classification codes — C23 (malignant neoplasm of gallbladder) |
| B. | Synonyms — gallbladder cancer, gallbladder adenocarcinoma, malignant tumor of the gallbladder, gallbladder carcinoma |
| C. | Adult onset — very high (mainly in the 60s–70s, female predominance) |
| 1. | History — epidemiology of high gallbladder cancer incidence in the Andean region and Chile; elucidation of the link between gallstones and gallbladder cancer |
| 2. | Causes — gallstones and chronic cholecystitis, gallbladder polyps, calcified gallbladder, Salmonella typhi, obesity, female hormones |
| 3. | Genetics — TP53, KRAS, ERBB2 (HER2) amplification (high frequency in Korea and Japan), CDKN2A, SMAD4 |
| 4. | Epidemiology — Chilean women have the highest incidence in the world; high incidence in India, Korea, and Japan; Korea has the 2nd highest mortality in the world |
| 5. | Pathophysiology — chronic irritation from gallstones→mucosal metaplasia→dysplasia→adenocarcinoma; tendency for direct invasion through the gallbladder wall |
| 6. | Symptoms — right upper quadrant pain, jaundice, nausea and vomiting, fatty food intolerance, weight loss, loss of appetite |
| 7. | Signs — right upper quadrant mass, Murphy sign, jaundice, elevated CA19-9 and CEA |
| 8. | Screening — no standard screening test; abdominal ultrasound follow-up for high-risk groups with gallstones or polyps; management of gallbladder polyps |
| 9. | Diagnosis — abdominal ultrasound, CT, MRI/MRCP; CA19-9; AJCC TNM 8th edition staging; incidental finding after laparoscopic cholecystectomy |
| 10. | Treatment — simple cholecystectomy (T1a); extended cholecystectomy (T1b or higher); gemcitabine+cisplatin±durvalumab |
| 11. | Prognosis — T1 5-year survival 85%; T2 50%; T3–T4 poor; median survival 6–12 months with distant metastasis |
| 12. | Prevention — appropriate management of gallstones (early removal of symptomatic gallstones), obesity prevention, treatment of H. pylori and Salmonella |
| 13. | References — NCCN biliary tract cancer guidelines, ABC-02, TOPAZ-1, 10 items on Korean biliary tract cancer epidemiology |
Special Copayment Reduction (V193): 5% copayment applied for 5 years from the cancer patient registration date
| Category | Details |
|---|---|
| ICD-10 code | C23 — malignant neoplasm of gallbladder (single code) |
| Korean Standard Classification of Diseases code | C23 (applied identically under KCD-8) |
| Special Copayment Reduction code | V193 |
| Main histological types | Adenocarcinoma about 85–95%, squamous cell carcinoma, adenosquamous carcinoma, neuroendocrine carcinoma, undifferentiated carcinoma, and others |
| Related codes | Clinically closely related to C24 (malignant neoplasm of other parts of biliary tract); gallbladder cancer and cholangiocarcinoma are collectively called biliary tract cancer |
Gallbladder cancer, gallbladder adenocarcinoma, malignant tumor of the gallbladder, gallbladder carcinoma, carcinoma of the gallbladder, gallbladder cancer. In the English medical literature it is included as a subcategory of biliary tract cancer and is distinguished from cholangiocarcinoma. Some literature includes gallbladder cancer in extrahepatic biliary cancer.
Gallbladder cancer is a disease with a very high frequency of adult onset, with a median age at diagnosis of about 65–72 years. It occurs about 2–3 times more often in women than in men (female predominance), which is related to sex differences in the frequency of gallstones and the effect of female hormones in promoting gallstone formation. Onset before age 40 is rare.
The most notable geographic feature in the history of gallbladder cancer is the abnormally high incidence in the Andes region, especially Chile. Chile is one of the countries with the highest incidence of gallbladder cancer in the world, and gallbladder cancer was one of the most common cancers in women there. This clustering was described in earnest in epidemiological studies in the 1970s–1980s and was analyzed as resulting from a combination of genetic predisposition (indigenous mapuche ancestry), high gallstone frequency, a high-fat diet, obesity, and other factors. Northern India (the Gangetic plain), Pakistan, Japan, and Korea are also high-incidence areas.
The link between gallbladder cancer and gallstones was first described in pathological studies in the late 19th century, and in 1929 Courvoisier systematically summarized the association between gallstones and gallbladder cancer. Subsequent epidemiological studies have repeatedly confirmed that the risk of gallbladder cancer is 2–10 times higher in patients with gallstones. The fact that chronic gallbladder carriage of Salmonella typhi increases the risk of gallbladder cancer was reported by Indian research teams, and toxins produced by S. typhi and chronic gallbladder inflammation have been suggested to contribute to carcinogenesis.
In the history of treatment, after laparoscopic cholecystectomy became widespread (1990s), gallbladder cancers found incidentally during surgery for gallstones (incidental gallbladder carcinoma) increased, and guidelines for reoperation (extended resection) were developed accordingly. In systemic therapy, the ABC-02 trial in 2010 established gemcitabine+cisplatin as the standard first-line treatment for advanced biliary tract cancer (including gallbladder cancer), and in 2022 the TOPAZ-1 trial demonstrated improved OS with gemcitabine+cisplatin+durvalumab (a PD-L1 inhibitor), which became the new standard.
Gallstones are the strongest risk factor for gallbladder cancer, present in about 70–90% of patients with gallbladder cancer. The risk of gallbladder cancer increases with larger gallstones (especially 3 cm or more) and a longer duration of gallstones. Chronic cholecystitis causes dysplasia, the stage preceding adenocarcinoma, through chronic mucosal irritation and inflammation from gallstones. Gallbladder polyps 1 cm or larger or growing rapidly have malignant potential and are an indication for cholecystectomy.
Porcelain gallbladder was previously known to carry a high risk of gallbladder cancer, but recent studies have shown that the risk differs according to the pattern of selective calcification. Chronic Salmonella typhi carriage increases the risk of gallbladder cancer in India and elsewhere, and an association with Helicobacter pylori infection of the gallbladder has also been reported. Obesity indirectly raises the risk of gallbladder cancer through gallstone formation. Female hormones and pregnancy promote cholesterol gallstone formation, and estrogen receptors are expressed in some gallbladder cancers. Primary sclerosing cholangitis (PSC), anomalous pancreaticobiliary junction, and gallbladder adenoma are also risk factors.
The molecular genetics of gallbladder cancer has recently been actively studied. The most common somatic mutations are TP53 (about 40–60%), KRAS (about 10–20%), CDKN2A (about 20–30%), and SMAD4 (about 15%). ERBB2 (HER2) amplification/overexpression is observed in about 15–20% of gallbladder cancers and is reported to be particularly frequent in Korean and Japanese patient groups. This provides the basis for the clinical application of HER2-targeted therapy (trastuzumab, pertuzumab).
Molecular heterogeneity between countries is marked: there are reports that in Korean biliary tract cancer, IDH1 mutations and FGFR2 fusions are less frequent and ERBB2 amplification is more frequent than in Western studies. PIK3CA mutations (about 10%), APC mutations, and ARID1A mutations are also observed in some cases. MSI-H (microsatellite instability-high) is observed in about 5–10% and serves as a biomarker predicting response to immune checkpoint inhibitor therapy. As hereditary factors, the risk of gallbladder cancer may be increased in patients with Lynch syndrome, BRCA1/2 mutations, and familial adenomatous polyposis (FAP).
Gallbladder cancer is the most common type of biliary tract cancer, with an estimated 110,000 cases annually worldwide. Chile has the world's highest incidence of gallbladder cancer in women, and it was once recorded as the most common cancer in women, surpassing cervical cancer (12–15 cases per 100,000 women). Northern India (the Gangetic plain) is also a high-incidence area, with 8–21 cases per 100,000 women reported. Korea has one of the highest overall mortality rates from biliary tract cancer in the world, and gallbladder cancer also shows a relatively high frequency (an estimated 3,000–4,000 cases per year in Korea).
By sex, in most regions of the world women are affected 2–3 times more often than men, which is related to the female bias of gallstones, obesity, and pregnancy. Only about 20–30% are localized lesions (stage I–II) at diagnosis, and about 60–70% are already advanced or metastatic at diagnosis, resulting in a poor prognosis. The declining incidence trend in Chile is associated with the expansion of laparoscopic cholecystectomy (early removal of gallstones).
The development of gallbladder cancer is understood as a multistep process of chronic gallstone irritation→mucosal metaplasia→dysplasia→carcinoma in situ→invasive adenocarcinoma. Repeated mechanical irritation and chronic inflammation from gallstones transform the normal columnar epithelium of the gallbladder mucosa into metaplastic epithelium, and in this process DNA damage, repair defects, and oxidative stress accumulate. The cytotoxicity of bile acids also aggravates damage to the gallbladder mucosa.
At the molecular level, loss of cell cycle arrest and apoptosis function due to TP53 mutations, CDK4/6 activation and promotion of the G1→S cell cycle transition due to CDKN2A (p16) loss, and constitutive activation of RAF-MEK-ERK signaling due to KRAS mutations are the key mechanisms of gallbladder carcinogenesis. ERBB2 amplification hyperactivates the PI3K-AKT-mTOR and RAS-MAPK pathways through formation of HER2-HER3 heterodimers. Because of the anatomical characteristic that the gallbladder epithelium readily invades directly through the hepatic surface (which has no visceral peritoneum), direct invasion of the liver occurs from an early stage.
Early gallbladder cancer is mostly asymptomatic and is often found incidentally on imaging during follow-up of gallstones or gallbladder polyps. When symptoms occur, the disease has often already advanced considerably. Right upper quadrant pain is the most common symptom (60–70%) and is difficult to differentiate because it resembles symptoms of cholecystitis or gallstones. Nausea and vomiting, indigestion, and fatty food intolerance (symptoms worsening after high-fat meals) accompany it. Weight loss and loss of appetite are prominent in advanced cancer.
Jaundice occurs when the tumor invades the common bile duct or when it is compressed by hilar lymph node metastasis, and is observed in about 30–40% of advanced cancers. Ascites, abdominal distension due to peritoneal dissemination, and loss of appetite, fatigue, and generalized weakness appear with distant metastasis.
On physical examination, a right upper quadrant mass may be palpable (direct palpation may be difficult because the liver covers the gallbladder tumor). Murphy sign (right upper quadrant tenderness and pain on inspiration) suggests gallbladder disease but is not specific to gallbladder cancer. With jaundice, yellow discoloration of the skin and sclera, dark urine, and pale stools are observed. Courvoisier gallbladder (a palpable, painless enlarged gallbladder) is a sign of malignant biliary obstruction but is more typical of pancreatic head cancer than of gallbladder cancer.
Serum CA19-9 is the most frequently used tumor marker and shows a sensitivity of about 70–79% in gallbladder cancer, but it can also be elevated in benign biliary diseases, so its specificity is limited. CEA and CA125 are also used as adjuncts. Elevated liver function tests (ALP, GGT, bilirubin) may reflect biliary obstruction.
There is currently no national standard screening program for gallbladder cancer. However, follow-up with abdominal ultrasound is recommended for people with the following risk factors: gallbladder polyps 1 cm or more in diameter (high malignant potential, cholecystectomy recommended); even for polyps under 10 mm, early resection is considered with HBV infection, accompanying gallstones, or rapid growth. For size-based follow-up and surgical criteria for gallbladder polyps, refer to the European ESGE guidelines (2017), the American ACR guidelines, and others. In high-risk groups for gallstones (elderly, obese, female, multiparous), early surgical treatment of symptomatic gallstones contributes indirectly to the prevention of gallbladder cancer.
Abdominal ultrasound is the primary screening tool and is useful for detecting masses, polyps, and wall thickening in the gallbladder. However, it is difficult to confirm gallbladder cancer or accurately determine its stage with ultrasound alone. Abdominal CT (triphasic dynamic contrast-enhanced) evaluates tumor extent, direct liver invasion, bile duct involvement, lymph node metastasis, and distant metastasis (liver, lung, peritoneum). MRI/MRCP is excellent for evaluating bile duct involvement and extent and also helps differentiate intrahepatic metastases. PET-CT is used for functional evaluation of distant and lymph node metastasis.
Gallbladder cancer is not infrequently found incidentally on pathological examination after laparoscopic cholecystectomy (incidental gallbladder cancer). For unresectable lesions, tissue diagnosis is established by CT-guided percutaneous biopsy or EUS-FNA. AJCC TNM 8th edition: T1a (mucosa), T1b (muscle layer), T2 (perimuscular connective tissue), T3 (invasion of liver, bile duct, or adjacent organs), T4 (invasion of the main portal vein or hepatic artery, or multiple organs); N1 (1–3 regional biliary lymph nodes), N2 (4 or more or distant lymph nodes); M1 (distant metastasis).
T1a (confined to the mucosa): simple laparoscopic cholecystectomy is sufficient, with a 5-year survival rate of 85% or more. T1b (muscle layer invasion): simple cholecystectomy or extended cholecystectomy including resection of liver segments 4b and 5 is recommended (varies by institution). T2 or higher: extended cholecystectomy including liver resection (safety margin of 2 cm or more) and hepatoduodenal ligament lymph node dissection. When T1b or higher is confirmed after laparoscopic cholecystectomy, reoperation (extended resection) is performed. With bile duct involvement, bile duct resection and biliary reconstruction are needed. Liver transplantation is being studied in some selected patients.
The first-line standard treatment for unresectable or metastatic gallbladder cancer is gemcitabine+cisplatin (ABC-02 trial, 2010). In the 2022 TOPAZ-1 trial, gemcitabine+cisplatin+durvalumab (a PD-L1 inhibitor) showed improved OS compared with placebo (median OS 12.8 months vs 11.5 months, HR 0.80) and has been added to the current standard. In 2023, KEYNOTE-966 also demonstrated an OS benefit with gemcitabine+cisplatin+pembrolizumab. As second-line treatment, FOLFOX (oxaliplatin+5-FU+leucovorin) showed efficacy in the ABC-06 trial. Trastuzumab-based regimens are being studied in HER2-positive gallbladder cancer.
Adjuvant chemoradiotherapy is considered after resection with positive margins (R1) or in high-risk groups (T3–T4, N-positive). With biliary obstruction, jaundice is relieved by biliary stent placement (ERCP or percutaneous route).
The prognosis of gallbladder cancer is largely determined by the stage at diagnosis. T1a (confined to the mucosa): 5-year survival rate 80–100%. T1b (muscle layer invasion): 5-year survival rate about 70–80%. T2: 5-year survival rate about 40–60%. T3 (direct liver invasion or invasion of adjacent organs): 5-year survival rate 10–30%. T4·M1 (distant metastasis): 5-year survival rate less than 5%, median OS 6–12 months.
Because gallbladder cancer has often already advanced at diagnosis, the overall 5-year survival rate is only about 18–20%. Surgical resectability (R0 resection) is the most important prognostic factor, and lymph node metastasis, margin status, and tumor differentiation also affect prognosis. If the gallbladder ruptures during laparoscopic cholecystectomy, the risk of peritoneal dissemination is high and the prognosis is poor.
Gallstone management: early removal by cholecystectomy for symptomatic gallstones is the most effective means of primary prevention. This is supported by the significant decrease in gallbladder cancer incidence in Chile after the spread of laparoscopic cholecystectomy. Obesity prevention and weight management: manage obesity and hyperlipidemia, the main risk factors for gallstone formation. Treatment of Salmonella typhi and H. pylori: antibiotic treatment of chronic gallbladder carriage may lower the risk of gallbladder cancer. Management of gallbladder polyps: cholecystectomy for polyps 1 cm or larger, and regular follow-up ultrasound for those under 1 cm. Preventing metabolic syndrome through a healthy diet (low-fat, high-fiber), abstaining from alcohol, and regular exercise also helps.